Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Menarini Industrie Farmaceutiche Riunite New York Germany Italy France Spain United Kingdom United States of America Switzerland Netherlands Belgium Austria

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype.The molecule has demonstrated strong preclinical activity. Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December. This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.View original content:https://www.prnewswire.co.uk/news-releases/menarini-group-and-insilico-medicine-enter-global-exclusive-license-agreement-for-novel-kat6-inhibitor-for-potential-breast-cancer-treatment-and-other-oncology-indications-302026491.html